Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Phagenesis Ltd.
With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.
September M&A deals picked up after a quiet summer with 23 M&A deals recorded, the busiest month of the year so far, which included two major deals closing at $4bn.
InSightec, TriVascular and NicOx are among firms with notable recent product approvals or launches.
Many patients lose their ability to swallow normally following a stroke. Using alternative feeding routes and hoping that the swallowing function returns spontaneously are standard of care, which fails to address the root cause of the problem. Soon to become commercialized, though, is technology from Britain’s Phagenesis Ltd. that allows for electrical stimulation of the pharynx so that another part of the brain can take over the swallowing control function.
- Medical Devices